ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Randomized Phase II VELO Clinical Trial: Panitumumab + Trifluridine/Tipiracil as Anti-EGFR Rechallenge Therapy in Chemo-Refractory RAS WT mCRC
By
ASCO GI 2023 Conference Coverage
FEATURING
Stefania Napolitano
By
ASCO GI 2023 Conference Coverage
FEATURING
Stefania Napolitano
138 views
February 16, 2023
Login to view comments.
Click here to Login
Videos